Physician profile
Mahmoud K Khaimi
NPI 1881745651
$1,306,745.19
in general payments reported to CMS, 2019-2025
20 companies · $194K in 2025
The $194K reported for 2025 was more than what 99% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286K · 2020: $1,539 · 2021: $173K · 2022: $238K · 2023: $136K · 2024: $277K · 2025: $194K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $549K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $27K · Travel and Lodging: $15K · Education: $7,979 · Food and Beverage: $7,650 · Honoraria: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $549,400.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $26,633.71 |
| Travel and Lodging | $14,773.06 |
| Education | $7,979.00 |
| Food and Beverage | $7,649.61 |
| Honoraria | $1,290.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $914,420.74 | 2021-2025 | |
| Ellexiscience | $224,832.24 | 2019 | |
| Lumibird Medical INC. | $61,290.70 | 2019 | |
| Iridex Corporation | $60,992.60 | 2019-2022 | |
| Ocular Therapeutix, INC. | $30,359.73 | 2021-2025 | Dextenza |
| Bausch & Lomb Americas INC. | $8,913.54 | 2022-2025 | Miebo, Vyzulta |
| Glaukos Corporation | $4,052.06 | 2025 | Preserflo Microshunt, Idosetr, Istent Infinite |
| Alcon Vision LLC | $699.98 | 2021-2025 | Simbrinza, Hydrus Microstent, Rocklatan |
| Abbvie INC. | $465.81 | 2022-2025 | |
| Sight Sciences, INC. | $296.95 | 2019-2022 | |
| Allergan, INC. | $151.37 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $96.65 | 2020-2021 | |
| Thea Pharma INC. | $42.14 | 2023-2024 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $32.64 | 2019 | |
| Rxsight INC | $28.07 | 2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $23.10 | 2025 | Syfovre |
| New World Medical,INC. | $20.80 | 2025 | Via360, Streamline, Kahook Dual Blade |
| Novartis Pharmaceuticals Corporation | $14.38 | 2019 | |
| Aerie Pharmaceuticals, INC. | $11.69 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmoud Khaimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.